Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service peripheral nerve stimulation & intrathecal pumps cases in South Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 11% on average (174 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 11 | 417 | 32% |
| 2020 | 8 | 456 | 35% |
| 2021 | 15 | 654 | 40% |
| 2022 | 15 | 591 | 43% |
| 2023 | 15 | 692 | 46% |
| 2024 | 17 | 936 | 48% |
| 2025 from claims | – | 1,507 1,218–1,769 | 49% |
| 2026 forecast | – | 1,670 1,308–2,098 | 50% |
| 2027 forecast | – | 1,844 1,367–2,438 | 50% |
| 2028 forecast | – | 2,036 1,441–2,810 | 51% |
| 2029 forecast | – | 2,247 1,527–3,222 | 51% |
| 2030 forecast | – | 2,480 1,624–3,680 | 52% |
PNS lead and generator, intrathecal pump and catheter. Professional codes (what the surgeon bills): CPT 64555, 64590, 62362, 62350.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 80% of the cases CMS names in South Carolina; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 58% hospital outpatient, 27% surgery center, 15% office. The share outside the hospital has moved +7 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center | Office |
|---|---|---|---|
| 2026 · ~1,700 | ~930 | ~490 | ~250 |
| 2027 · ~1,800 | ~1,000 | ~560 | ~280 |
| 2028 · ~2,000 | ~1,100 | ~630 | ~310 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 31% (27% in 2025), hospital outpatient about 54% (58% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 60 | 4,698+15%/yr | +15%/yr | 2.0 | 72% | 9,310 in 2030+12%/yr |
| Florida | 65 | 3,941+8.8%/yr | +8.8%/yr | 1.6 | 74% | 5,860 in 2030+6.8%/yr |
| Georgia | 20 | 1,195+14%/yr | +14%/yr | 1.3 | 62% | 2,360 in 2030+12%/yr |
| North Carolina | 21 | 1,154+13%/yr | +13%/yr | 1.1 | 42% | 1,560 in 2030+5.2%/yr |
| Tennessee | 23 | 1,041+6.2%/yr | +6.2%/yr | 1.4 | 47% | 2,170 in 2030+13%/yr |
| Oklahoma | 21 | 1,024+2.9%/yr | +2.9%/yr | 2.0 | 28% | 1,160 in 2030+2.1%/yr |
| Arkansas | 21 | 852+4.7%/yr | +4.7%/yr | 2.1 | 57% | 980 in 2030+2.4%/yr |
| Kentucky | 14 | 792+1.1%/yr | +1.1%/yr | 1.6 | 17% | 700 in 2030−2%/yr |
| Maryland | 12 | 704+23%/yr | +23%/yr | 0.8 | 89% | 1,180 in 2030+9%/yr |
| Virginia | 13 | 571−0.7%/yr | −0.7%/yr | 0.5 | 30% | 670 in 2030+2.7%/yr |
| Mississippi | 13 | 445+2.3%/yr | +2.3%/yr | 1.1 | 76% | 590 in 2030+4.7%/yr |
| Louisiana | 4 | 441+6.5%/yr | +6.5%/yr | 1.0 | 46% | 410 in 2030−1.4%/yr |
| Alabama | 6 | 319+4.8%/yr | +4.8%/yr | 0.7 | 49% | 670 in 2030+13%/yr |
| West Virginia | 3 | 158+6.2%/yr | +6.2%/yr | 0.7 | 27% | 100 in 2030−7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Radiofrequency ablation (facet, genicular, basivertebral) | 107 | 7,768−1.3%/yr | −1.3%/yr | 10.90.8× | 87% | 8,970 in 2030+2.4%/yr |
| Spinal cord & DRG stimulation | 21 | 702−4.7%/yr | −4.7%/yr | 1.01.0× | 36% | 710 in 2030+0.1%/yr |
Peripheral nerve stimulation & intrathecal pumps in every state, and its device makers · Every procedure market in South Carolina · Every state · Compare with Texas
Curonix leads with 24% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 10 companies reported engagement with South Carolina’s surgeons worth $115K in consulting, speaking, meals and travel tied to these products, about $6,740 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 13 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.